In the dynamic world of biopharmaceutical manufacturing, not all profound changes arrive with a fanfare of press releases. Often, the most significant shifts occur quietly, behind the scenes, as companies strategically recalibrate their positions in response to evolving market forces. Since late 2023, the Contract Development and Manufacturing Organization (CDMO) sector has been undergoing precisely such a transformation – a comprehensive modality realignment that savvy investors, biotech leaders, and industry observers simply cannot afford to ignore. This isn’t merely a cyclical adjustment; it’s an existential re-evaluation of capabilities, focus, and long-term viability, reshaping how biotech products are developed and brought to market.

We’ve tracked a distinct wave of strategic maneuvers: deliberate pivots by major players, calculated divestitures of non-core assets, impactful mergers and acquisitions, and targeted expansions into high-growth niches. These actions are collectively redrawing the competitive landscape, creating new opportunities while simultaneously exposing vulnerabilities. Understanding these shifts – who is quietly exiting high-risk modalities, and who remains deeply committed to specific therapeutic spaces – is paramount for navigating the future of pharmaceutical manufacturing, partnership dynamics, and talent acquisition.

This deep dive will unravel the complex interplay of financial pressures, technological advancements, and strategic imperatives driving this unprecedented realignment. We will explore the macro forces at play, detail the strategic pivots of leading CDMOs, examine modality-specific expansions and contractions, and analyze the significant role of private equity and the emergence of specialized niche players. Ultimately, we will shed light on the profound implications for the entire biopharmaceutical ecosystem.

The Macro Forces Driving Realignment: A Perfect Storm

The current CDMO landscape is a direct reflection of a perfect storm of macroeconomic conditions and evolving industry demands. Persistent inflation, elevated interest rates, and a significantly constrained venture capital funding environment – particularly for early-stage biotechnology companies – have created substantial headwinds. This financial pressure on drug developers directly translates to pressure on CDMOs, impacting their capacity utilization, revenue forecasts, and growth outlook.

The cell and gene therapy (CGT) sector, for instance, experienced a notable contraction in investment in 2024. This scarcity of investor financing for nascent biotechs has had a devastating impact on CDMOs whose business models were heavily reliant on serving these early-phase ventures. A stark example is the complete closure of AmplifyBio, a CDMO specializing in early-stage cell and gene therapy, mRNA, and plasmid products. The company directly attributed its demise to a “downturn in the market for early-stage development of cell and gene therapies,” which “stymied its ability to grow” due to scarce investor financing. This tragic outcome underscores the precarious position of CDMOs that are overly specialized in volatile, capital-intensive early-stage market segments.

Beyond funding, the post-pandemic world has introduced its own set of challenges. The frenetic capacity building seen during the COVID-19 era, particularly in vaccine manufacturing, led to periods of overcapacity. As pandemic-related demand waned, a market correction ensued, compelling CDMOs to reassess and rationalize their manufacturing footprints. This “great reset” in biopharma funding and capacity has forced CDMOs to become leaner and more specialized, favoring those with robust financial health, established clienteles, or distinctive technological advantages that cater to late-stage and commercial manufacturing needs.

Simultaneously, the therapeutic landscape is undergoing a rapid evolution. Advanced therapies such as cell and gene therapies, Antibody-Drug Conjugates (ADCs), and radiopharmaceuticals are inherently complex and costly to manufacture. They demand specialized facilities, highly skilled personnel, and stringent regulatory compliance, all contributing to high operational expenses for CDMOs. This high degree of specialization, while creating significant barriers to entry for competitors, also makes CDMOs vulnerable if demand within their specific niche falters. Repurposing these expensive, highly tailored facilities for other therapeutic modalities is often difficult and economically unviable, leading to underutilized assets if anticipated growth does not materialize as quickly as projected.

Finally, geopolitical factors are increasingly influencing CDMO strategies. Discussions surrounding legislation like the U.S. BIOSECURE Act, even if not fully enacted, have prompted drug developers to explore alternative service providers and supply chain diversification. This underlying concern about supply chain security and geopolitical tensions persists, encouraging a longer-term trend towards diversification and potentially favoring CDMOs with global footprints or strategic locations in allied nations, a concept often referred to as “friend-shoring.”

These multifaceted pressures are collectively driving a “flight to quality and capability,” where CDMOs are not merely expanding but are strategically acquiring specific, often niche, expertise and technologies. This drive is a direct response to the increasingly complex demands of next-generation therapeutics emerging from pharmaceutical and biotechnology pipelines.

Major CDMOs: Strategic Pivots and Divestitures Reshaping the Giants

The largest players in the CDMO space are not immune to these macro forces; in fact, their strategic maneuvers often have the most significant ripple effects across the industry. We’ve seen several major CDMOs undertake profound pivots and divestitures since late 2023, signaling a clear shift in their core business focus.

Lonza: The “One Lonza” Vision and a Bold Bet on Biologics

Lonza, a behemoth in the CDMO world, has embarked on a significant strategic overhaul under its “One Lonza” vision, announced in December 2024. This initiative represents a clear commitment to becoming a pure-play CDMO, shedding non-core assets to sharpen its focus on high-growth pharmaceutical services.

A cornerstone of this strategy is the planned exit from its Capsules & Health Ingredients (CHI) business. This divestiture allows Lonza to concentrate resources entirely on its core CDMO offerings. The company has reorganized into three integrated business units: Integrated Biologics (covering biologics drug substance and drug product), Advanced Synthesis (small molecules and bioconjugates, including ADCs), and Specialized Modalities (cell, gene, and mRNA technologies). This restructuring is designed to enhance agility and service delivery in key growth areas.

Further solidifying its commitment to large-scale biologics, Lonza acquired Roche-Genentech’s Vacaville site for $1.2 billion in 2024. This acquisition significantly expands Lonza’s biologics capacity, positioning it to meet the burgeoning demand for large-scale biomanufacturing. By divesting non-CDMO segments and strategically acquiring critical capacity, Lonza is proactively reshaping its portfolio to solidify its leadership in the most dynamic areas of pharmaceutical manufacturing.

Catalent: Acquired by Novo Holdings and Realigned for GLP-1 Dominance

Perhaps the most impactful transaction in the CDMO sector during this period was the $16.5 billion acquisition of Catalent Inc. by Novo Holdings, the parent company of Novo Nordisk, announced in February 2024 and completed by late 2024. This deal is a prime example of a major pharmaceutical company leveraging its investment arm to secure critical manufacturing capacity for its blockbuster drugs.

As part of this transaction, Novo Nordisk acquired three of Catalent’s key sterile fill/finish facilities—located in Bloomington, Indiana (USA), Anagni (Italy), and Brussels (Belgium)—for $11 billion. This strategic move was explicitly driven by Novo Nordisk’s urgent and massive need for manufacturing capacity to support its blockbuster GLP-1 agonist drugs, Ozempic and Wegovy.

The implications are profound: these three large, high-quality fill/finish plants are effectively removed from the open CDMO market. While Novo Nordisk has stated it will honor existing contracts, it is widely assumed these facilities will primarily, if not exclusively, serve Novo Nordisk’s internal needs long-term. This could significantly tighten sterile fill/finish capacity for other drug developers, particularly for complex biologics requiring aseptic processing. The deal also took Catalent, one of the largest pure-play CDMOs, off the public equity market, reducing publicly available financial data for the sector. Despite the asset transfer, the Catalent brand remains under Novo Holdings’ private ownership, continuing to operate its numerous other global sites as a CDMO. This event demonstrates a willingness by Big Pharma to vertically integrate or form very close alignments with CDMOs for critical manufacturing capabilities, potentially reshaping the traditional sponsor-CDMO relationship for certain product classes.

Recipharm: Sharpening Focus Through Strategic Divestitures

Swedish CDMO Recipharm, backed by private equity firm EQT, has also undergone a significant strategic realignment. In April 2024, the company announced the divestiture of seven manufacturing sites across Sweden, France, and Spain to Blue Wolf Capital Partners. This move was part of a deliberate effort to sharpen Recipharm’s focus.

The divested sites were primarily involved in small-molecule and solid-dose manufacturing. By shedding these legacy assets, Recipharm is now concentrating on higher-margin, high-growth areas: oral solid dosage for New Chemical Entities (NCEs) and on-patent drugs, sterile fill-finish (particularly lyophilization and pre-filled syringes), and biologics through its ReciBioPharm division, which specializes in nucleic acids and viruses. This repositioning aims to elevate Recipharm’s standing as a leading CDMO in Europe for these specialized areas, moving it out of lower-margin segments and into areas of growing demand, such as peptide hormone fill-finish and advanced biologics.

Emergent BioSolutions: A Full Exit from Third-Party CDMO

Emergent BioSolutions made a decisive move to exit the third-party CDMO market in 2025, a broad strategic pivot rather than a targeted retreat from a specific advanced therapeutic modality. This strategy was executed through the divestiture of key manufacturing facilities.

The company sold its Baltimore-Camden drug product (fill/finish) facility to Bora Pharmaceuticals and its Baltimore-Bayview drug substance (monoclonal antibody) manufacturing facility to Syngene International. Emergent’s stated rationale for these divestitures aligns with a broader corporate restructuring aimed at creating a “leaner and more flexible organization,” improving profitability, and reducing debt. While the divested facilities possessed capabilities that could support advanced therapies, Emergent’s exit was driven by overarching financial and strategic goals to reshape the company, not by a specific negative assessment of the prospects for CGT, ADCs, or radiopharma within the CDMO space. The acquisition of these assets by Bora Pharmaceuticals and Syngene International suggests other entities perceive value and opportunity in this CDMO capacity.

Siegfried: Deprioritizing Vaccines for Core Strengths

Switzerland-based Siegfried, in its 2024 annual results released in February 2025, disclosed that it had phased out its vaccine production business. This segment had provided a boost during the COVID-19 pandemic, but as pandemic-related demand waned, Siegfried chose to realign.

This strategic shift reflects a return to Siegfried’s core strengths in small-molecule APIs and drug products. The company’s new EVOLVE+ strategy, introduced in late 2024, reinforces a focus on operational excellence and targeted growth, including support for cell and gene therapy development, while explicitly de-emphasizing vaccines. Siegfried’s withdrawal from vaccine projects illustrates a therapeutic-area shift to concentrate on its primary CDMO services, adapting to the post-pandemic market reality.

Modality-Specific Deep Dive: Expansions and Contractions

The strategic shifts among major CDMOs are mirrored by a nuanced landscape of expansions and contractions within specific therapeutic modalities. While some areas are experiencing a “shakeout,” others are witnessing aggressive investment and capacity building.

Cell & Gene Therapy (CGT): A Shakedown and Targeted Growth

The CGT CDMO space has been particularly volatile. Despite the immense therapeutic promise, manufacturing complexities, high costs of goods, and lengthy development timelines, coupled with a cautious funding environment for early-stage CGT biotechs, have led to significant restructuring. The “investment in CGT developers ‘nosedived’ in 2024,” directly impacting the project flow to specialized CDMOs. This segment appears to be undergoing a shakeout, with smaller or early-stage focused players being particularly vulnerable.

Beyond AmplifyBio’s closure, other notable contractions include:

• Rentschler Biopharma (Stevenage, UK): Announced in January 2025 its strategic decision to exit the cell and gene therapy manufacturing space to focus on its core biologics business, citing slower-than-anticipated growth in the CGT market.
• National Resilience (Durham, NC, USA): Is reducing its workforce by 120 employees at its gene therapy facility, responding to reduced demand.
• Thermo Fisher Scientific (Massachusetts, USA): Has undertaken significant consolidation of its viral vector manufacturing capabilities, including the closure of its Lexington, MA, site and layoffs across multiple locations, aiming for optimized resource and network utilization.
• Charles River Laboratories (Various US Sites): Has been rightsizing its CGT operations, with layoffs and consolidation of smaller sites due to lower demand.
• Novartis (San Diego, CA, USA): Is closing its San Diego gene therapy manufacturing facility.
• Tenaya Therapeutics (California, USA): Announced a significant staff reduction and will make its manufacturing facility dormant as part of restructuring.
• Astellas Gene Therapies (San Francisco, CA, USA): Is winding down its San Francisco biomanufacturing facility.
• Lyell Immunopharma (Los Angeles, CA, USA): Is shutting down its Los Angeles manufacturing facility, consolidating production elsewhere.

However, amidst this contraction, targeted expansions by smaller, specialized players are also evident:

• ENCell (Seoul, South Korea): Secured a CDMO contract with Cellebrain and partnered with Japan’s Cell Resources to expand into the Japanese CGT market, focusing on technology transfer and consulting.
• MEDINET (Tokyo, Japan): Formed a strategic partnership with AGC, parent company of AGC Biologics, to accelerate its cell therapy CDMO business in Japan, leveraging AGC’s global network.
• Made Scientific (formerly BioCentriq, Princeton, NJ, USA): Rebranded to underscore its sharpened focus on cell therapy development and manufacturing, launching a new 60,000 square foot facility with significant investment.
• PCI Pharma Services: Significantly bolstered its CGT and sterile fill-finish capabilities through the acquisition of Ajinomoto Althea, Inc. This strategic move provides PCI with its first North American manufacturing site for prefilled syringes and cartridges, including isolator technology, and enhances its high-potent manufacturing capabilities for ADCs.

The difficulties in the CGT CDMO sector point towards a likely continuation of consolidation, where larger, financially stable CDMOs may acquire distressed assets or innovative technologies from smaller players. For pharmaceutical companies developing CGTs, this environment necessitates exceptionally rigorous due diligence when selecting CDMO partners, focusing on their financial health, proven operational expertise, and long-term viability.

Antibody-Drug Conjugates (ADCs): High Growth, Developer Volatility

The Antibody-Drug Conjugate (ADC) market is characterized by intense research and development, a rapidly growing pipeline, and increasing clinical successes, leading to projections of substantial market growth (projected to hit $19B by 2030). ADCs are complex therapeutics requiring specialized manufacturing expertise in areas such as monoclonal antibody production, cytotoxic payload synthesis, linker chemistry, conjugation processes, and the handling and fill/finish of highly potent compounds. This complexity makes CDMOs with dedicated ADC capabilities critical partners.

The restructuring activity in this segment is nuanced: while dedicated ADC CDMOs are investing and expanding, the fortunes of ADC developer companies significantly influence the overall ecosystem.

• Samsung Biologics: Announced in January 2025 the launch of new end-to-end ADC services at its dedicated facility, leveraging its expertise in large-scale monoclonal antibody production to meet rising demand. This marks a strategic modality expansion beyond mAbs into ADCs.
• Lonza (Visp, Switzerland): As part of its “One Lonza” strategic realignment, Lonza is investing in new ADC manufacturing suites, a clear signal of capacity expansion to meet growing demand.
• Abzena (Bristol, PA, USA): Invested $5 million in March 2024 to expand its bioconjugation and ADC capabilities, adding new equipment and optimizing laboratories.
• Veranova (Devens, MA, USA): Initiated a $30-million expansion of its ADC and highly potent compound development and manufacturing capabilities in June 2024.

However, the primary turbulence comes from the developer side, where clinical trial outcomes or financial pressures can lead to rapid program changes and restructurings, directly influencing demand for CDMO services:

• BioAtla (USA): Announced a major workforce reduction in March 2025 to extend its cash runway and focus on lead clinical ADC programs.
• Elevation Oncology (USA): Following underwhelming Phase I results for its ADC, the company announced a significant staff reduction and discontinued the program.
• Pyxis Oncology (USA): Reduced its headcount to streamline operations and dedicate resources to its lead ADC candidate.
• Sutro Biopharma (San Carlos, CA, USA): Announced it was halving its workforce and would shut down its manufacturing-support facility by the end of 2025 as part of a strategic shift to focus on next-generation ADCs.
• Vincerx Pharma (USA): Announced in April 2025 that it was winding down its operations due to “extremely challenging financial markets,” halting its ADC development programs.
• MacroGenics (Rockville, MD, USA): Discontinued the development of a B7-H3-targeting ADC after it failed to meet efficacy endpoints in a Phase 2 trial.

The ADC CDMO segment itself is not seeing widespread closures; rather, it is characterized by strategic investments by established players to build highly specialized capacity. The primary turbulence comes from the developer side, where clinical trial results and funding availability can lead to rapid program changes and restructurings.

Radiopharmaceuticals: Aggressive Expansion and Vertical Integration

In stark contrast to the pressures seen in some other advanced therapy areas, the radiopharmaceutical CDMO sector appears to be in a phase of active growth, consolidation through strategic mergers and acquisitions, and significant investment. This dynamism is fueled by rapid advancements in theranostics (the combination of therapy and diagnostics), an increasing demand for targeted cancer treatments, and the expansion of applications for radiopharmaceuticals beyond oncology.

No specific announcements of facility closures, significant downsizing, or workforce reductions focused primarily on radiopharmaceutical CDMOs were identified in the analyzed period. Instead, the key activities revolve around aggressive expansion and capability building:

• PharmaLogic Holdings Corp.: Announced in April 2025 its acquisition of a majority stake in Agilera Pharma AS, a Norway-based radiopharmaceutical manufacturing company. This move aims to create “the first fully-integrated, worldwide CDMO focusing on radiopharmaceutical therapies.” PharmaLogic also opened new radiopharmaceutical production facilities in Los Angeles, CA, and Salt Lake City, UT, in October 2024.
• Lantheus Holdings: Has been particularly active in acquisitions, entering agreements to acquire Evergreen Theragnostics (a radiopharmaceutical CDMO with manufacturing capabilities) and Life Molecular Imaging. These moves aim to bolster Lantheus’s pipeline and manufacturing capabilities, notably bringing radioligand therapy (RLT) manufacturing infrastructure in-house to reduce reliance on third-party manufacturers.
• Nucleus RadioPharma (Rochester, MN, USA): Announced plans in October 2024 to open new manufacturing facilities in Arizona and Pennsylvania, expected to be complete by the end of 2026, aiming to triple its manufacturing capacity for radiopharmaceuticals.

The current activity suggests that the primary challenge in the radiopharmaceutical CDMO market is not overcapacity or lack of demand, but rather ensuring sufficient specialized manufacturing infrastructure, managing the complexities of short half-life isotopes, and navigating stringent regulatory pathways. Companies developing radiopharmaceuticals will likely find a competitive but evolving CDMO landscape, emphasizing partners with requisite specialized infrastructure, licenses, and robust regulatory track records.

Private Equity Reshuffling and the Rise of Niche Players

Beyond the strategic maneuvers of large, publicly traded CDMOs, private equity (PE) firms are playing an increasingly influential role in reshaping the sector. PE-backed CDMOs are actively optimizing their portfolios through divestitures, mergers, and acquisitions, often aimed at specializing in high-growth areas or consolidating capabilities to offer more comprehensive services.

Private Equity’s Active Hand

• CoreRx + Societal CDMO: CoreRx, backed by QHP Capital, completed the acquisition of Societal CDMO in April 2024 for approximately $130 million. This merger created an enhanced CDMO with broad capabilities spanning early-stage formulation development to commercial manufacturing and packaging, particularly in small molecule therapeutics.
• MedPharm + Tergus Pharma: In July 2024, MedPharm, backed by Ampersand Capital Partners, merged with Tergus Pharma, supported by Great Point Partners. The combined entity operates under the MedPharm name, establishing a leading end-to-end CDMO for topical and transepithelial pharmaceuticals, integrating expertise from formulation to commercial production.
• Avid Bioservices: This biologics-focused CDMO was acquired by GHO Capital Partners and Ampersand Capital Partners in February 2025 for $1.1 billion. The private equity firms plan to support Avid’s next phase of growth by expanding its service offerings and geographic reach in biologics manufacturing, leveraging their extensive experience in the CDMO sector.
• Recipharm (revisited): As highlighted earlier, Recipharm’s strategic divestiture of seven manufacturing sites was a direct result of its PE backing by EQT, aiming to sharpen its focus on higher-value areas like biologics and sterile fill-finish.

These transactions underscore how private equity is driving consolidation and specialization, seeking to create more focused and efficient CDMO platforms that can command higher valuations by addressing specific market demands.

The “Rising Fast” Smaller CDMOs: Carving Out Niches

Amidst the consolidation and strategic repositioning by the giants, a cohort of smaller, highly specialized CDMOs are rapidly gaining traction by carving out critical niches and demonstrating agility. These companies are often characterized by their deep expertise in specific modalities, innovative technologies, or flexible service models that cater to the unique needs of biotech innovators.

• Nucleus RadioPharma: Headquartered in Rochester, MN, this company is aggressively expanding its radiopharma footprint across three US hubs. Its plans to open new manufacturing facilities in Arizona and Pennsylvania, expected to triple manufacturing capacity, directly address critical supply chain challenges in this niche but growing field.
• Korean CDMOs (ENCell and MEDINET): In Asia, ENCell (Seoul, South Korea) is doubling down on CGT, securing significant CDMO contracts and partnering with Japan’s Cell Resources for market entry. Similarly, MEDINET (Tokyo, Japan) formed a strategic partnership with AGC (parent company of AGC Biologics) to accelerate its cell therapy CDMO business in Japan, leveraging larger networks for global expansion. These collaborations illustrate how smaller CDMOs can gain traction in specialized areas through strategic alliances.
• Abzena and Veranova: These companies are making significant investments to enhance their capabilities in Antibody-Drug Conjugates (ADCs) and Highly Potent Active Pharmaceutical Ingredients (HPAPIs). Abzena, headquartered in San Diego, CA, invested $5 million to expand its bioconjugation capacity in Bristol, Pennsylvania. Veranova initiated a $30-million expansion of its ADC capabilities in Devens, Massachusetts. These targeted investments reflect a response to the rising demand for specialized bioconjugation services.

These smaller players demonstrate that while scale and broad capabilities are important, deep specialization and strategic partnerships can enable significant growth and market relevance. They are often more nimble, able to adapt quickly to emerging needs and provide highly customized solutions that larger, more diversified CDMOs might find challenging to offer.

Conclusion: Implications and Future Outlook

The period from January 2024 through May 2025 has been one of profound recalibration for the global CDMO sector. The observed trends of facility closures, workforce reductions, strategic downsizing, and significant consolidation are not merely indicative of a cyclical downturn but rather point to a structural evolution of the industry. This evolution is being driven by the increasing complexity of new therapeutic modalities, the immense financial stakes involved in their development and commercialization, and a more discerning investor climate. The CDMO landscape is undeniably becoming more sophisticated, with the technical and regulatory complexity inherent in manufacturing CGTs, complex biologics, and radiopharmaceuticals meaning the barrier to entry for CDMOs is high and continues to rise.

For Investors: Navigating the Bifurcated Market

For investors, this realignment is more than strategic; it’s existential. The market is increasingly bifurcating into “haves” and “have-nots.” The “haves” are typically well-capitalized, technologically advanced CDMOs – often larger entities or highly specialized niche players – that can invest in new capabilities and meet the stringent demands of modern drug development. The “have-nots” may include CDMOs struggling with older facilities, a lack of distinct specialization, or weaker financial footing, making them more vulnerable to prevailing market pressures.

Understanding who is quietly exiting high-risk, early-stage modalities (like some CGT players) and who remains deeply committed to specific, high-growth spaces (like GLP-1 fill-finish or radiopharmaceuticals) is paramount. Investment decisions must now scrutinize not just a CDMO’s current capacity, but its long-term strategic commitment to specific modalities, its financial robustness, and its ability to adapt to rapid technological advancements. The Catalent-Novo deal, for instance, highlights a new paradigm where a major pharmaceutical company directly secures critical manufacturing assets, signaling a potential shift in how supply chain security is valued and acquired.

For Biotech and Pharma Leaders: The Imperative of Due Diligence

For pharmaceutical and biotechnology companies seeking to scale their pipelines, the current CDMO landscape necessitates heightened vigilance in partner selection and relationship management. The financial health of a CDMO, its technological capabilities, its regulatory track record, and its strategic alignment with the sponsor’s long-term product and portfolio goals will be more critical than ever.

The trend of large pharmaceutical companies securing dedicated capacity may require smaller and mid-sized biotechs to engage with CDMOs earlier and more strategically to secure future manufacturing slots, particularly for high-demand services like sterile fill/finish or highly specialized ADC conjugation. Any contraction or shift in CDMO capacity could also potentially impact development timelines and costs if preferred partners are no longer available or if capacity becomes concentrated among fewer, potentially less flexible, larger CDMOs. The emphasis will be on finding partners who offer not just capacity, but deep, specialized expertise and a proven track record of navigating the complexities of advanced therapies.

Evolving Pharma-CDMO Relationships and the Future Outlook

The relationship between pharmaceutical companies and CDMOs is likely to evolve towards more integrated and strategic partnerships. This shift moves beyond purely transactional service provision to encompass deeper collaborations, particularly for complex and advanced therapies where manufacturing intricacies are closely tied to product success. This could foster new collaboration models, including risk-sharing arrangements and co-investment in dedicated facilities or technologies.

Talent acquisition and retention will also remain a critical factor. The specialized nature of advanced therapy manufacturing demands highly skilled personnel, and the ongoing shifts in the CDMO landscape will undoubtedly impact the talent pool. CDMOs that can attract, develop, and retain top talent will have a significant competitive advantage. Furthermore, the ability of CDMOs to adapt to rapid technological advancements, such as the integration of artificial intelligence in process development and manufacturing, will be critical for future success.

Despite the current headwinds affecting certain segments, the fundamental demand for advanced therapies is projected to continue its upward trajectory, driven by ongoing innovation in oncology, rare diseases, and other areas. This underlying growth will ultimately support a dynamic, albeit potentially reshaped, CDMO ecosystem dedicated to bringing these transformative treatments to patients worldwide. The CDMOs that successfully weather this turbulence will be those that are agile, specialized, financially robust, and deeply aligned with the evolving needs of the global biopharmaceutical industry. The realignment is indeed more than strategic; it’s a fundamental recalibration for the future of medicine.

Hiring in CDMO? Need some guidance/advice? Click here to talk to us directly: www.progensearch.com/talk-to-uk